SEARCH

SEARCH BY CITATION

References

  • Alonzi D. S., Neville D. C. A., Lachmann R. H., Dwek R. A. and Butters T. D. (2008) Glucosylated free oligosaccharides are biomarkers of endoplasmic-reticulum alpha-glucosidase inhibition. Biochem. J. 409, 571580.
  • Andersson U., Butters T. D., Dwek R. A. and Platt F. M. (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821829.
  • Andersson U., Reinkensmeier G., Butters T., Dwek R. A. and Platt F. M. (2004) Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Biochem. Pharmacol. 67, 697705.
  • Ando S., Chang N. C. and Yu R. K. (1978) High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal. Biochem. 89, 437450.
  • Arfi A., Bourgoin C., Basso L. et al. (2005) Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts. Neurobiol. Dis. 20, 583593.
  • Bae J. S. and Kim B. J. (2005) Cerebellar ataxia and acute motor axonal neuropathy associated with Anti GD1b and Anti GM1 antibodies. J. Clin. Neurosci. 12, 808810.
  • Baek R. C., Lee J. P., Seyfried T. N. and Snyder E. Y. (2005) Neural stem cell transplantation reduces brain GM2 and GA2 content in a mouse model of Sandhoff disease. J. Neurochem. 94, 21.
  • Baek R. C., Kasperzyk J. L., Platt F. M. and Seyfried T. N. (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem. Int. 52, 11251133.
  • Begley D., Pontikis C. and Scarpa M. (2008) Lysosomal storage diseases and the blood-brain barrier. Curr. Pharm. Des. 14, 15661580.
  • Cox T., Lachmann R., Hollak C. et al. (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 14811485.
  • Denny C. A., Kasperzyk J. L., Gorham K. N., Bronson R. T. and Seyfried T. N. (2006) Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. J. Neurosci. Res. 83, 10281038.
  • Duan W., Guo Z., Jiang H., Ware M., Li X. J. and Mattson M. P. (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl Acad. Sci. USA 100, 29112916.
  • Elstein D., Hollak C., Aerts J. M. F. G. et al. (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis. 27, 757766.
  • Galjaard H. (1980) Genetic Metabolic Disease: Diagnosis and Prenatal Analysis. Elsevier Sicence Publishers, Amsterdam.
  • Giraldo P., Latre P., Alfonso P. et al. (2006) Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher’s disease. Haematologica 91, 703706.
  • Gjedde A. and Crone C. (1975) Induction processes in blood-brain transfer of ketone bodies during starvation. Am. J. Physiol. 229, 11651169.
  • Gravel R. A., Clarke J. T. R., Kaback M. M., Mahuran D., Sandhoff K. and Suzuki K. (1995) The GM2 gangliosidoses. in The Metabolic and Molecular Bases of Inherited Disease (ScriverC. R., BeaudetA. L., SlyW. S. and ValleD., eds), Vol. II, pp. 28392879. McGraw-Hill, Inc., New York.
  • Greene A. E., Todorova M. T., McGowan R. and Seyfried T. N. (2001) Caloric restriction inhibits seizure susceptibility in epileptic EL mice by reducing blood glucose. Epilepsia 42, 13711378.
  • Hasselbalch S. G., Knudsen G. M., Jakobsen J., Hageman L. P., Holm S. and Paulson O. B. (1995) Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am. J. Physiol. 268, E1161E1166.
  • Hauser E. C., Kasperzyk J. L., D’Azzo A. and Seyfried T. N. (2004) Inheritance of lysosomal acid b-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem. Genet. 42, 241257.
  • Jeyakumar M., Butters T. D., Cortina-Borja M., Hunnam V., Proia R. L., Perry V. H., Dwek R. A. and Platt F. M. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 63886393.
  • Jeyakumar M., Norflus F., Tifft C. J., Cortina-Borja M., Butters T. D., Proia R. L., Perry V. H., Dwek R. A. and Platt F. M. (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97, 327329.
  • Kasperzyk J. L., El-Abbadi M. M., Hauser E. C., D’Azzo A., Platt F. M. and Seyfried T. N. (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J. Neurochem. 89, 645653.
  • Kasperzyk J. L., D’Azzo A., Platt F. M., Alroy J. and Seyfried T. N. (2005) Substrate reduction therapy reduces ganglioside content in postnatal cerebrum-brainstem and cerebellum in a mouse model of GM1 gangliosidosis. J. Lipid Res. 46, 744751.
  • Lee C. K., Weindruch R. and Prolla T. A. (2000) Gene-expression profile of the ageing brain in mice. Nat. Genet. 25, 294297.
  • Macala L. J., Yu R. K. and Ando S. (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J. Lipid Res. 24, 12431250.
  • Mahoney L. B., Denny C. A. and Seyfried T. N. (2006) Caloric restriction in C57BL/6J mice mimics therapeutic fasting in humans. Lipids Health Dis. 5, 13.
  • Mantis J. G., Centeno N., Todorova M. T., McGowan R. and Seyfried T. N. (2003) Metabolic control of epilepsy in adult EL mice with the ketogenic diet and caloric restriction. Epilepsia 44(Suppl. 9), 6465.
  • Mellor H. R., Adam A., Platt F. M., Dwek R. A. and Butters T. D. (2000) High-performance cation-exchange chromatography and pulsed amperometric detection for the separation, detection, and quantitation of N-alkylated imino sugars in biological samples. Anal. Biochem. 284, 136142.
  • Morgan T. E., Xie Z., Goldsmith S., Yoshida T., Lanzrein A.-S., Stone D., Rozovsky I., Perry G., Smith M. A. and Finch C. E. (1999) The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 89, 687699.
  • Mukherjee P., El-Abbadi M. M., Kasperzyk J. L., Ranes M. K. and Seyfried T. N. (2002) Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer 86, 16151621.
  • Norflus F., Tifft C. J., McDonald M. P., Goldstein G., Crawley J. N., Hoffmann A., Sandhoff K., Suzuki K. and Proia R. L. (1998) Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101, 18811888.
  • Platt F. M., Neises G. R., Reinkensmeier G., Townsend M. J., Perry V. H., Proia R. L., Winchester B., Dwek R. A. and Butters T. D. (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N- butyldeoxynojirimycin. Science 276, 428431.
  • Platt F. M., Jeyakumar M., Andersson U., Heare T., Dwek R. A. and Butters T. D. (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 947954.
  • Pollay M. and Stevens F. A. (1980) Starvation-induced changes in transport of ketone bodies across the blood-brain barrier. J. Neurosci. Res. 5, 163172.
  • Priestman D. A., Van Der Spoel A. C., Butters T. D., Dwek R. A. and Platt F. M. (2008) N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice. Diabetes Obes. Metab. 10, 159166.
  • Pugh T. D., Klopp R. G. and Weindruch R. (1999) Controlling caloric consumption: protocols for rodents and rhesus monkeys. Neurobiol. Aging 20, 157165.
  • Ranes M. K., El-Abbadi M., Manfredi M. G., Mukherjee P., Platt F. M. and Seyfried T. N. (2001) N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Br. J. Cancer 84, 11071114.
  • Sandhoff K. and Kolter T. (2003) Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 847861.
  • Sango K., Yamanaka S., Hoffmann A. et al. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11, 170176.
  • Seyfried T. N., Glaser G. H. and Yu R. K. (1978) Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J. Neurochem. 31, 2127.
  • Seyfried T. N., Bernard D., Mayeda F., Macala L. and Yu R. K. (1984) Genetic analysis of cerebellar lipids in mice susceptible to audiogenic seizures. Exp. Neurol. 84, 590595.
  • Sugimoto H., Wakata N., Kishi M., Fujioka T., Kurihara T., Irie Y. and Saito T. (2002) A case of Guillain-Barré syndrome associated with cerebellar ataxia and positive serum anti-GD1b IgG antibody. J. Neurol. 249, 346347.
  • Tifft C. J. and Proia R. L. (2000) Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology 10, 12491258.
  • Todorova M. T., Tandon P., Madore R. A., Stafstrom C. E. and Seyfried T. N. (2000) The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy. Epilepsia 41, 933940.
  • Treiber A., Morand O. and Clozel M. (2007) The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor. Xenobiotica 37, 298314.
  • Veech R. L. (2004) The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 70, 309319.
  • Weindruch R. and Walford R. L. (1988) The retardation of aging and disease by dietary restriction. Thomas, Springfield, Illinois.
  • Willenbrock F. W., Neville D. C., Jacob G. S. and Scudder P. (1991) The use of HPLC-pulsed amperometry for the characterization and assay of glycosidases and glycosyltransferases. Glycobiology 1, 223227.
  • Williamson D. H., Mellanby J. and Krebs H. A. (1962) Enzymic determination of D(-)-beta-hydroxybutyric acid and acetoacetic acid in blood. Biochem. J. 82, 9096.